Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.

doi:10.1016/j.meegid.2016.09.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases - 1 Nov 2016

Unissa Ameeruddin Nusrath, Subbian Selvakumar, Hanna Luke Elizabeth, Selvakumar Nagamiah

Abstract excerpt

Isoniazid (INH) is one of the most active compounds used to treat tuberculosis (TB) worldwide. In addition, INH has been used as a prophylactic drug for individuals with latent Mycobacterium tuberculosis (MTB) infection to prevent reactivation of disease. Importantly, the definition of multidrug resistance (MDR) in TB is based on the resistance of MTB strains to INH and rifampicin (RIF). Despite its simple...

Topics

Antitubercular Agents
Bacterial Proteins
Drug Resistance, Bacterial
Humans
Isoniazid
Mutation
Mycobacterium tuberculosis
Tuberculosis

Source

Open in PubMed

Identifiers

PMID: 27612406
DOI: 10.1016/j.meegid.2016.09.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics